Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) is one of the best biotech penny stocks to buy according to analysts. On ...
ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...
Epidermal growth factor receptor (EGFR) is a protein on the surface of your cells that helps them grow. When the gene that codes for EGFR has a mutation, it affects the way this protein works, causing ...
The epidermal growth factor receptor (EGFR)/ERBB family has evolved from a primordial, simple pathway of a single ligand receptor pair to a complex signalling network. Studies in invertebrates and in ...
For years, Nichole Jefferson battled a series of health problems as she juggled a stressful job in the tech industry while raising her daughter. Then, in 2003, she wasn’t feeling well and went to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback